We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA net sales increased by almost 700% year over year to $113 million in 2025. Revenue is expected to reach $180 million in 2026. A possible label expansion for ANKTIVA in 2027 may be supported by positive QUILT- ...

We recently published 10 Big Names With Painful Declines. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on Tuesday. ImmunityBio extended losses for a third day on Tuesday, shedding 4.19 percent to close at $5.95 apiece as investors continued to take profits after recording 14 straight days of gains last week. For the entire month of January until Thursday, January 22, ImmunityBio Inc. (NASDAQ:IBRX) has already soared by 271 percent following a flurry of positive developments, including ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving ImmunityBio, Inc. and its officers or directors [1] Group 1: Company Developments - On January 23, 2026, ImmunityBio announced updated Phase 2 clinical results from the QUILT 3.078 trial, which focuses on a chemotherapy-free combination immunotherapy for patients with recurrent or progressive glioblastoma [3] - The press release indicated that the median overall survival, the primary endpoint of the trial, has not yet been reached [3] - Following this announcement, ImmunityBio's stock price decreased by $0.89 per share, representing a 12.13% decline, closing at $6.45 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of ImmunityBio to discuss claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month. Trading volume reached 74.6 million shares, coming in about 238% above its three-month average of 22.1 million shares. ImmunityBio IPO'd in 2015 and has fallen 83% since going public. How the markets moved today The broader markets were relatively steady Friday, with the S&P 500 (SNPINDEX:^GSPC) edging up 0.03% to 6,915 a ...

Company Overview - ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies aimed at enhancing the immune system to combat infectious diseases and various cancers [2]. Stock Performance - The stock has experienced significant gains, with an increase of over 130% since a recent comment was aired, and a year-to-date rise of over 220% [3]. Analyst Opinions - Jim Cramer expressed skepticism about ImmunityBio, indicating that the company has been unprofitable for an extended period and does not favor the stock as a good investment [2]. - Cramer suggested that investors should consider taking profits on the stock due to its substantial price increase following an FDA meeting [1]. Investment Comparison - While acknowledging the potential of IBRX, it is noted that certain AI stocks may present greater upside potential and lower downside risk compared to ImmunityBio [3].

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.NASDAQ : IBRXImmunityBioToday's Change( 6.79 %) $ 0.44Current Price$ 6.92Key Data PointsMarket Cap$6.4BDay's Range$ 5.71 - $ 7.1052wk Range$ 1.83 - $ 7.98Volume96MAvg Vol19MGross Margin80.41 %ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what ...

Key Takeaways IBRX surged 17.4% after FDA talks aligned on the regulatory path for Anktiva in papillary NMIBC.ImmunityBio finished the requested analyses and plans an sBLA resubmission within a month, with no new study.IBRX's QUILT-3.032 study (Cohort B) met its endpoint, showing durable clinical efficacy with Anktiva.Shares of ImmunityBio (IBRX) surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align on the regulatory path forward for Anktiva in an additional indica ...

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] Industry Overview - Wall Street is investing hundreds of billions into AI technologies, but there is a critical question regarding the energy supply needed to sustain this growth [2] - AI technologies, particularly data centers for large language models, consume vast amounts of electricity, comparable to the energy needs of small cities [2] - The energy demands of AI are expected to increase, leading to potential strain on power grids and rising electricity prices [2] Company Insights - A specific company is highlighted as a key player in the energy infrastructure sector, poised to benefit from the increasing energy demands of AI [3][6] - This company owns critical nuclear energy infrastructure assets and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7] - The company is positioned to profit from the surge in U.S. LNG exports, particularly under the current administration's energy policies [7] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization [8] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without high premiums [9] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off the radar compared to other AI and energy stocks [10] - The company is trading at less than 7 times earnings, indicating a potentially attractive investment opportunity [10] Future Outlook - The convergence of AI, energy infrastructure, and onshoring trends presents a unique investment landscape, with the potential for significant returns as the demand for energy in AI applications grows [14][15]

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path. Trading volume reached 209.3 million shares, about 1,000% above its three-month average of 19.1 million shares. ImmunityBio IPO'd in 2015 and has fallen 81% since going public. How the markets moved today ...

Core Insights - ImmunityBio Inc. plans to submit additional information to the FDA regarding its supplemental biologics license application for Anktiva in treating papillary non-muscle invasive bladder cancer (NMIBC) within 30 days [1][2] - The stock has seen significant trading activity, with a session volume of 178.91 million compared to an average of 15.9 million [1] FDA Interaction - The FDA provided feedback during discussions on Anktiva in combination with Bacillus Calmette-Guérin for patients with BCG-unresponsive papillary NMIBC, which supports a potential resubmission of the sBLA filed initially in 2025 without requiring a new clinical trial [2] Clinical Results - Updated clinical results presented included over five years of follow-up data, showing disease-specific survival of approximately 96% at 36 months and cystectomy avoidance rates of 92% at one year and 82% at three years [3][4] - The safety profile of Anktiva is consistent with its currently approved indication in carcinoma in situ [4] Trial Data - The QUILT-3.032 Phase 2/3 trial, which enrolled 80 patients with high-grade, papillary-only BCG-unresponsive NMIBC, met its primary endpoint with a 12-month disease-free survival rate of 58.2% and progression-free survival rates of 94.9% at 12 months and 83.1% at 36 months [5] Market Performance - Anktiva is already approved in the U.S. and several international markets for BCG-unresponsive NMIBC with carcinoma in situ [6] - Preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a 700% year-over-year increase [7] - For Q4 2025, revenue was about $38.3 million, marking a 20% quarter-over-quarter increase and a 431% year-over-year increase [7] Analyst Ratings - Piper Sandler maintains an Overweight rating for ImmunityBio and raises the price forecast from $5 to $7, while D. Boral Capital maintains a Buy rating with a price forecast of $24 [8] - ImmunityBio shares were up 20.44% at $6.64, reaching a new 52-week high [8]